NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it has been granted conditional approval for its fluorescence in situ hybridization (FISH)-based ROS1 lung cancer biomarker assay from the New York State Department of Health (NYSDOH).

With the decision, the company said its ROS1 FISH assay, which was acquired through Rosetta's purchase of PersonalizeDx earlier this year, is now available in all 50 US states.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.